Platinum-resistant recurrent epithelial ovarian cancer (OC), fallopian tube cancer (FTC), and primary peritoneal cancer (PPC) represent a particularly challenging clinical scenario. These diseases share similar molecular and clinical features, with high rates of ...Learn More

In the field of biopharmaceuticals, the quest for safer and more sustainable alternatives to traditional plasma-derived proteins has led to exciting developments. One such breakthrough is the Recombinant Human Albumin Injection derived from Oryza sativa (rice), a plant-based ...Learn More

Diffuse Large B-Cell Lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, accounting for approximately 30-40% of diagnosed cases in adults. This aggressive disease is characterized by the rapid proliferation of malignant lymphoid B cells, and although the standard ...Learn More

Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) represent a significant challenge in hematology, affecting thousands worldwide with their insidious progression and resistance to traditional therapies. As researchers and clinicians, we're always on the ...Learn More

As a passionate advocate for advancements in biotechnology and global pharmaceuticals, I'm thrilled to share an update on the vibrant ecosystem of Chinese innovative drug exporters. China has solidified its position as a key engine in research and development (R&D) of ...Learn More